Ads
related to: novartis ag (nvs)- Contact Us
Contact a PYLARIFY sales
representative to stay updated.
- Resources for PYLARIFY
Discover downloadable guides for
health care professionals.
- PYLARIFY Imaging Sites
Find or register a PYLARIFY
imaging site.
- PYLARIFY Updates
Be among the first to receive new
imaging locations & news updates.
- Contact Us
Search results
Novartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 months agoNovartis AG (NYSE:NVS) Q4 2023 Earnings Call Transcript January 31, 2024 Novartis AG misses on...
Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know
Zacks via Yahoo Finance· 2 months agoZacks.com users have recently been watching Novartis (NVS) quite a bit. Thus, it is worth knowing...
Novartis (NVS) Plans to Spin-Off Sandoz in Early October
Zacks via Yahoo Finance· 9 months agoNovartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October)...
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Zacks via Yahoo Finance· 1 month agoNovartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2024 results on Apr 23....
Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View
Zacks via Yahoo Finance· 7 months agoSwiss pharma giant Novartis AG NVS reported strong sales from key drugs in third-quarter 2023 and...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 1 month agoSwiss pharma giant Novartis AG NVS reported better-than-expected results for the first quarter of...
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
Zacks via Yahoo Finance· 8 months agoNovartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically...
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
Zacks via Yahoo Finance· 2 years agoNovartis AG NVS reported mixed second-quarter 2022 results. The Sandoz business continues to recover...
Novartis (NVS) Announces Positive Data on Oncology Drug
Zacks via Yahoo Finance· 2 years agoNovartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall...
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Zacks via Yahoo Finance· 1 month agoNovartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for...
